Who Paid My Doc
George Paletta
Neuromusculoskeletal Medicine, Sports Medicine Chesterfield, MO Medical Doctor
NPI 1497720825 CMS profile 22009
14825 N Outer 40, Suite 200, Chesterfield, MO 63017
General payments
$30,177
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, George Paletta of Chesterfield, MO is reported in the CMS Open Payments database as having received $30,177 across 119 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 97th percentile of Neuromusculoskeletal Medicine, Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,318 | 12 | |
| 2024 | General | $3,825 | 20 | |
| 2023 | General | $3,412 | 20 | |
| 2022 | General | $2,564 | 5 | |
| 2021 | General | $5,685 | 25 | |
| 2020 | General | $1,490 | 7 | |
| 2019 | General | $10,884 | 30 |
Beside peers
- George Paletta
- Neuromusculoskeletal Medicine, Sports Medicine median
- Middle half of Neuromusculoskeletal Medicine, Sports Medicine
- National median
In program year 2025, general payments to George Paletta were reported at $2,318. Among 69 Neuromusculoskeletal Medicine, Sports Medicine profiles paid that year, the median was $125 and the middle half received between $37 and $473.
Show as a table
| Year | George Paletta | Neuromusculoskeletal Medicine, Sports Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $10,884 | $152 | $43–$474 | $163 |
| 2020 | $1,490 | $113 | $31–$725 | $114 |
| 2021 | $5,685 | $167 | $50–$469 | $132 |
| 2022 | $2,564 | $132 | $46–$572 | $149 |
| 2023 | $3,412 | $109 | $39–$366 | $160 |
| 2024 | $3,825 | $115 | $37–$321 | $164 |
| 2025 | $2,318 | $125 | $37–$473 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
12
Drug cost
$2
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Meloxicam | Generic | 12 | $2 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.
Records
119 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neuromusculoskeletal Medicine, Sports Medicine in Missouri
Related records
Neuromusculoskeletal Medicine, Sports Medicine in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Neuromusculoskeletal Medicine, Sports Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.